Security
AURORA CANNABIS INC WT EXP 05/31/2025 (Canada) · ACBWF
ACBWFOTCWarrantHistorical · closed Apr 27, 2023CIK 1683541Updated Oct 27, 2026
Current securities for this SEC filerACB · NASDAQACB · TSX
ACBWF price & chart
About the company
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · CADSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCAD | 1,591,000Source | -69,326,000Source | -1,717,979,000Source | -695,089,000Source |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsCAD | 11,524,000Source | 12,717,000Source | 13,757,000Source | 20,243,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -11,453,000Source | 105,000Source | -1,915,000Source | 3,420,000Source |
| GeneralAndAdministrativeExpenseCAD | 97,257,000Source | 92,222,000Source | 113,212,000Source | 119,437,000Source |
| GoodwillCAD | 43,871,000Source | 43,180,000Source | 0Source | 887,737,000Source |
| IncreaseDecreaseInWorkingCapitalCAD | -10,210,000Source | 15,627,000Source | -52,652,000Source | -397,000Source |
| InterestPaidClassifiedAsOperatingActivitiesCAD | 6,844,000Source | 11,700,000Source | 27,725,000Source | 34,157,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 5,240,000Source | 5,627,000Source | 7,545,000Source | 5,416,000Source |
| ProceedsFromIssuingSharesCAD | 0Source | 37,926,000Source | 350,188,000Source | 666,026,000Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodCAD | 5,488,000Source | 4,993,000Source | 0Source | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCAD | — | — | 19,648,000Source | 19,241,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesCAD | 7,245,000Source | 3,042,000Source | 0Source | — |
income statement · annual statements
| Line item | Q4 2022 | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseCAD | — | — | 144,159,000Source | 175,237,000Source | — |
| Total RevenueCAD | — | — | — | 221,339,000Source | 245,252,000Source |
| Additional Financial Items | |||||
| ApplicableTaxRatenumber | — | 0.27Source | 0.27Source | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareCAD/shares | — | 0.04Source | -1.52Source | -7.99Source | — |
| CurrentTaxExpenseIncomeCAD | — | 7,808,000Source | 1,109,000Source | 52,000Source | 122,000Source |
| DeferredTaxExpenseIncomeCAD | — | -3,189,000Source | -1,663,000Source | -2,193,000Source | -6,443,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossCAD | — | — | — | — | -6,542,000Source |
| DepreciationAndAmortisationExpenseCAD | — | 9,080,000Source | 12,139,000Source | 48,602,000Source | 49,174,000Source |
| DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssetsCAD | — | 27,445,000Source | — | — | — |
| DilutedEarningsLossPerShareCAD/shares | — | 0.04Source | -1.52Source | -7.99Source | — |
| FinanceCostsCAD | — | 8,420,000Source | 14,186,000Source | 71,813,000Source | 66,437,000Source |
| GainsLossesRecognisedWhenControlInSubsidiaryIsLostCAD | — | — | 0Source | 0Source | 0Source |
| GeneralAndAdministrativeExpenseCAD | — | 97,257,000Source | 92,222,000Source | 113,212,000Source | 119,437,000Source |
| GrossProfitCAD | — | 187,607,000Source | 131,460,000Source | 21,225,000Source | -21,558,000Source |
| ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentIncludingRightofuseAssetsCAD | — | 696,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsCAD | — | 4,619,000Source | -554,000Source | -2,141,000Source | -6,321,000Source |
| InterestExpenseOnLeaseLiabilitiesCAD | — | 2,921,000Source | 3,152,000Source | 3,433,000Source | 4,597,000Source |
| ProfitLossAttributableToNoncontrollingInterestsCAD | — | — | — | -355,000Source | — |
| ProfitLossAttributableToOwnersOfParentCAD | — | — | — | -1,717,624,000Source | — |
| ProfitLossBeforeTaxCAD | — | 20,382,000Source | -59,599,000Source | -1,720,120,000Source | -699,798,000Source |
| ProfitLossFromOperatingActivitiesCAD | — | 4,948,000Source | -46,453,000Source | -231,449,000Source | -282,818,000Source |
| ResearchAndDevelopmentExpenseCAD | — | 3,676,000Source | 3,572,000Source | 10,389,000Source | 11,447,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodCAD | — | — | — | 293,000Source | 509,000Source |
Filing attachments
ex991.htm · 6-K · 2026-10-26
Exhibit 99.1 Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application before the Alberta Securities Commission confirms Aurora's ATM program is compliant with Securities laws. The company reaffirms the last day Aurora used the ATM was August 18, …
Read attachment ↗ex991.htm · 6-K · 2026-10-14
Exhibit 99.1 Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board. Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders. Shareholders are advised to REJECT the revised Hostile Bid and TAKE NO ACTI…
Read attachment ↗ex991.htm · 6-K · 2026-10-08
Exhibit 99.1 Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output NASDAQ | TSX: ACB Multi-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output. ────────────────────────────────────────────────────────────────────────────────────────────── Enhanced facility adopts Aurora's proven cultivation practices and proprietary genetics to s…
Read attachment ↗ex991.htm · 6-K · 2026-10-07
Exhibit 99.1 Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway Aurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete. Shareholders are advised to TAKE NO ACTION pending a formal recommendation. Aurora shareholders will have until at least December 4, 2026, to consider their options. …
Read attachment ↗ex991.htm · 6-K · 2026-10-06
Exhibit 99.1 Aurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hostile Bid NASDAQ | TSX: ACB Curaleaf has yet to file a Notice of Variation and Change to revise its offer. Once filed, the Special Committee will complete a thorough and comprehensive review prior to issuing a formal recommendation to shareholders Aurora's application to the Alberta Securities Commission delivered results for shareholders: Curaleaf's l…
Read attachment ↗ex991.htm · 6-K · 2026-09-24
Exhibit 99.1 Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure NASDAQ | TSX: ACB Aurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws. Aurora intends to demonstrate that Curaleaf's Circular has not satisfied several regulatory requirements, impacting Aurora Shareholders, includin…
Read attachment ↗